Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Glioblastoma 10Astrocytoma 9Glioma 8Brain Neoplasms 7Oligodendroglioma 6Gliosarcoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Cyclophosphamide 2vocimagene amiretrorepvec 1veliparib 1sacituzumab govitecan 1paclitaxel-Angiopep-2 conjugate 1lenvatinib 1irinotecan sucrosofate 1iniparib 1fludarabine 1depatuxizumab mafodotin 1cabozantinib 1bintrafusp alfa protein, human 1aldesleukin 1Platinum 1Nivolumab 1NVP-BKM120 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Metformin 1Mebendazole 1Ipilimumab 1Interleukin-2 1Flucytosine 1Doxycycline 1Cisplatin 1Capecitabine 1Atorvastatin 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Flucytosine × CNS × Clear all
NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

Phase 1 Terminated
21 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Head and Neck Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡